GlassScriptPhysician profile
Jos R Santz
NPI 1376509299
$7,661.80
in general payments reported to CMS, 2019-2025
41 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $1,595 · 2021: $1,384 · 2022: $885 · 2023: $1,152 · 2024: $969 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.12 |
| Education | $136.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.13 | 2019-2025 | Jardiance |
| Abbvie INC. | $733.98 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $663.19 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $580.78 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $576.78 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $569.78 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $483.75 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sanofi-Aventis U.S. LLC | $329.67 | 2020-2022 | |
| Pfizer INC. | $328.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.86 | 2020-2025 | Trintellix |
| Amarin Pharma, INC. | $202.92 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.81 | 2022-2025 | |
| Corcept Therapeutics | $166.69 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $115.16 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $105.58 | 2019-2022 | |
| Abbott Laboratories | $102.65 | 2021-2024 | Eterna, Freestyle Libre 2 |
| Exact Sciences Corporation | $68.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $60.75 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $60.46 | 2022-2023 | Nuzyra |
| Horizon Therapeutics Plc | $59.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $50.57 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $49.02 | 2022-2023 | Quviviq |
| Currax Pharmaceuticals LLC | $42.52 | 2023 | Nexletol, Contrave |
| Allergan, INC. | $41.39 | 2019-2020 | |
| Bausch Health US, LLC | $39.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.94 | 2022-2023 | |
| Eisai INC. | $32.96 | 2021-2022 | |
| Daiichi Sankyo INC. | $31.22 | 2023-2025 | Injectafer |
| Gilead Sciences, INC. | $30.15 | 2020 | |
| Medtronic, INC. | $25.50 | 2023 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $22.32 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $21.90 | 2024 | Uptravi, Opsumit |
| Biogen, INC. | $21.72 | 2025 | Spinraza, Qalsody |
| Aytu Biopharma, INC. | $19.34 | 2019 | |
| Seqirus USA INC | $18.72 | 2025 | Fluad, Flucelvax |
| Edwards Lifesciences Corporation | $15.89 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zyla Life Sciences, INC. | $14.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.69 | 2020 | |
| Genentech USA, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jos Santz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.